IMDELLTRA® DEMONSTRATED SUPERIOR OVERALL SURVIVAL IN SMALL CELL LUNG CANCER

Core Insights - Amgen's IMDELLTRA® (tarlatamab-dlle) has shown a substantial survival advantage over standard chemotherapy in patients with small cell lung cancer (SCLC) who have progressed after platinum-based chemotherapy, as demonstrated in the Phase 3 DeLLphi-304 clinical trial [1][2][3] Group 1: Clinical Trial Results - The DeLLphi-304 trial met its primary endpoint, showing statistically significant and clinically meaningful improvement in overall survival (OS) compared to local standard-of-care chemotherapy [1][3] - IMDELLTRA is indicated for adult patients with extensive-stage SCLC who have disease progression on or after platinum-based chemotherapy, with approval based on overall response rate and duration of response [5][6] Group 2: Drug Mechanism and Target Population - IMDELLTRA is a first-in-class immunotherapy that targets DLL3 on tumor cells and CD3 on T cells, leading to the destruction of DLL3-expressing SCLC cells [4][6] - DLL3 is expressed on approximately 85-96% of SCLC patients, making it a promising target for therapy [4][6] Group 3: Safety and Efficacy - The safety profile of IMDELLTRA was consistent with its known profile, and detailed data from the trial will be presented at an upcoming medical congress [2][3] - Serious adverse reactions occurred in 58% of patients, with cytokine release syndrome (CRS) being the most common [26][27] Group 4: Future Developments - Amgen is advancing a robust development program for tarlatamab, including multiple ongoing clinical trials evaluating its efficacy in various treatment settings for SCLC [8][9]